The Role of Direct Oral Anticoagulants in the Treatment of Cancer-Associated Venous Thromboembolism: Review by Middle East and North African Experts

References

• Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458–464. doi:10.1001/archinte.166.4.458
   PubMed Web of Science ®Google Scholar
• Cohen AT, Katholing A, Rietbrock S, Bamber L, Martinez C. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer: a population-based cohort study. Thromb Haemost. 2017;117(01):57–65. doi:10.1160/TH15-08-0686
   PubMedGoogle Scholar
• Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632–634. doi:10.1111/j.1538-7836.2007.02374.x
   PubMed Web of Science ®Google Scholar
• Khorana AA. Venous thromboembolism and prognosis in cancer. Thromb Res. 2010;125(6):490–493. doi:10.1016/j.thromres.2009.12.023
   PubMed Web of Science ®Google Scholar
• Lip GY, Chin BS, Blann AD. Cancer and the prothrombotic state. Lancet Oncol. 2002;3(1):27–34. doi:10.1016/S1470-2045(01)00619-2
   PubMed Web of Science ®Google Scholar
• Ahlbrecht J, Dickmann B, Ay C, et al. Tumor grade is associated with venous thromboembolism in patients with cancer: results from the Vienna cancer and thrombosis study. J Clin Oncol. 2012;30(31):3870–3875. doi:10.1200/JCO.2011.40.1810
   PubMed Web of Science ®Google Scholar
• Cronin-Fenton DP, Søndergaard F, Pedersen LA, et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997–2006. Br J Cancer. 2010;103(7):947–953. doi:10.1038/sj.bjc.6605883
   PubMed Web of Science ®Google Scholar
• Streiff MB. Thrombosis in the setting of cancer. Hematology. 2016;2016(1):196–205. doi:10.1182/asheducation-2016.1.196
   PubMedGoogle Scholar
• Mulder FI, Horváth-Puhó E, van Es N, et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood. 2021;137(14):1959–1969. doi:10.1182/blood.2020007338
   PubMed Web of Science ®Google Scholar
• Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015;12(8):464–474. doi:10.1038/nrcardio.2015.83
   PubMed Web of Science ®Google Scholar
• Heit JA, Lahr BD, Ashrani AA, Petterson TM, Bailey KR. Predictors of venous thromboembolism recurrence, adjusted for treatments and interim exposures: a population-based case-cohort study. Thromb Res. 2015;136(2):298–307. doi:10.1016/j.thromres.2015.06.030
   PubMed Web of Science ®Google Scholar
• Addo-Tabiri NO, Chudasama R, Vasudeva R, et al. Black patients experience highest rates of cancer-associated venous thromboembolism. Am J Clin Oncol. 2020;43(2):94–100. doi:10.1097/COC.0000000000000639
   PubMed Web of Science ®Google Scholar
• Aleem A, Diab ARA, Alsaleh K, et al. Frequency, clinical pattern and outcome of thrombosis in cancer patients in Saudi Arabia. Asian Pac J Cancer Prev. 2012;13(4):1311–1315. doi:10.7314/APJCP.2012.13.4.1311
   PubMedGoogle Scholar
• Omunakwe H, Nwagha T. Cancer-associated thrombosis in some African populations: a growing concern. Int J Noncommun Dis. 2016;1(2):87. doi:10.4103/2468-8827.192017
   Google Scholar
• Prandoni P, Lensing AWA, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484–3488. doi:10.1182/blood-2002-01-0108
   PubMed Web of Science ®Google Scholar
• Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: burden, mechanisms, and management. Thromb Haemost. 2017;117(02):219–230. doi:10.1160/TH16-08-0615
   PubMedGoogle Scholar
• O’Connell C, Escalante CP, Goldhaber SZ, McBane R, Connors JM, Raskob GE. Treatment of cancer-associated venous thromboembolism with low-molecular-weight heparin or direct oral anticoagulants: patient selection, controversies, and caveats. oncologist. 2021;26(1):e8–e16. doi:10.1002/onco.13584
   PubMed Web of Science ®Google Scholar
• Attia D, Khorana AA. Evolving treatment options for cancer-related venous thromboembolism. JACC. 2020;2(3):441–442. doi:10.1016/j.jaccao.2020.06.003
   Google Scholar
• Lee AYY. Anticoagulant therapy for venous thromboembolism in cancer. N Engl J Med. 2020;382(17):1650–1652. doi:10.1056/NEJMe2004220
   PubMed Web of Science ®Google Scholar
• Moik F, Posch F, Zielinski C, Pabinger I, Ay C. Direct oral anticoagulants compared to low‐molecular‐weight heparin for the treatment of cancer‐associated thrombosis: updated systematic review and meta‐analysis of randomized controlled trials. Res Pract Thrombo Haemost. 2020;4(4):550–561. doi:10.1002/rth2.12359
   PubMed Web of Science ®Google Scholar
• Yan Y-D, Ding Z, Pan M-M, et al. Net clinical benefit of direct oral anticoagulants in patients with cancer and venous thromboembolism: a systematic review and trade-off analysis. Front Cardiovas Med. 2020;7:586020. doi:10.3389/fcvm.2020.586020
   PubMed Web of Science ®Google Scholar
• Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005;23(10):2123–2129. doi:10.1200/jco.2005.03.133
   PubMed Web of Science ®Google Scholar
• Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost. 2006;12(4):389–396. doi:10.1177/1076029606293692
   PubMed Web of Science ®Google Scholar
• Hull RD, Pineo GF, Brant RF, et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am j Med. 2006;119(12):1062–1072. doi:10.1016/j.amjmed.2006.02.022
   PubMed Web of Science ®Google Scholar
• Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002;162(15):1729. doi:10.1001/archinte.162.15.1729
   PubMed Web of Science ®Google Scholar
• Carrier M, Cameron C, Delluc A, Castellucci L, Khorana AA, Lee AYY. Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. Thromb Res. 2014;134(6):1214–1219. doi:10.1016/j.thromres.2014.09.039
   PubMed Web of Science ®Google Scholar
• Kahale LA, Hakoum MB, Tsolakian IG, et al. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev. 2018;2022(6). doi:10.1002/14651858.CD006650.pub5
   Google Scholar
• Al-Hameed F, Al-Dorzi HM, Al Momen A, et al. Prophylaxis and treatment of venous thromboembolism in patients with cancer: the Saudi clinical practice guideline. Ann Saudi Med. 2015;35(2):95–106. doi:10.5144/0256-4947.2015.95
   PubMed Web of Science ®Google Scholar
• Dorgalaleh A, Beigi P, Pakjoo M, et al. Anticoagulation therapy in Iran. Ann Blood. 2019;4:26. doi:10.21037/aob.2019.11.01
   Google Scholar
• Ay C, Beyer-Westendorf J, Pabinger I. Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants. Ann Oncol. 2019;30(6):897–907. doi:10.1093/annonc/mdz111
   PubMed Web of Science ®Google Scholar
• Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest. 2021;160(6):e545–e608. doi:10.1016/j.chest.2021.07.055
   PubMed Web of Science ®Google Scholar
• Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382(17):1599–1607. doi:10.1056/NEJMoa1915103
   PubMed Web of Science ®Google Scholar
• McBane RD, Wysokinski WE, Le‐Rademacher JG, et al. Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost. 2020;18(2):411–421. doi:10.1111/jth.14662
   PubMed Web of Science ®Google Scholar
• Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615–624. doi:10.1056/NEJMoa1711948
   PubMed Web of Science ®Google Scholar
• Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36(20):2017–2023. doi:10.1200/JCO.2018.78.8034
   PubMed Web of Science ®Google Scholar
• Planquette B, Bertoletti L, Charles-Nelson A, et al. Rivaroxaban vs dalteparin in cancer-associated thromboembolism. Chest. 2022;161(3):781–790. doi:10.1016/j.chest.2021.09.037
   PubMed Web of Science ®Google Scholar
• Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38(5):496–520. doi:10.1200/JCO.19.01461
   PubMed Web of Science ®Google Scholar
• Khorana AA, Noble S, Lee AYY, et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost. 2018;16(9):1891–1894. doi:10.1111/jth.14219
   PubMed Web of Science ®Google Scholar
• Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543–603. doi:10.1093/eurheartj/ehz405
   PubMed Web of Science ®Google Scholar
• Farge D, Frere C, Connors JM, et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019;20(10):e566–e581. doi:10.1016/s1470-2045(19)30336-5
   PubMed Web of Science ®Google Scholar
• Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927–974. doi:10.1182/bloodadvances.2020003442
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: cancer-associated venous thromboembolic disease, version 2.2021; 2021. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed August 16, 2021.
   Google Scholar
• Streiff MB, Abutalib SA, Farge D, Murphy M, Connors JM, Piazza G. Update on guidelines for the management of cancer-associated thrombosis. Oncologist. 2021;26(1):e24–e40. doi:10.1002/onco.13596
   PubMed Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799–808. doi:10.1056/NEJMoa1302507
   PubMed Web of Science ®Google Scholar
• EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al. Oral Rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499–2510. doi:10.1056/NEJMoa1007903
   PubMed Web of Science ®Google Scholar
• EINSTEIN–PE Investigators, Büller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287–1297. doi:10.1056/NEJMoa1113572
   PubMed Web of Science ®Google Scholar
• Hokusai-VTE Investigators, Büller HR, Décousu H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406–1415. doi:10.1056/NEJMoa1306638
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342–2352. doi:10.1056/NEJMoa0906598
   PubMed Web of Science ®Google Scholar
• Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129(7):764–772. doi:10.1161/CIRCULATIONAHA.113.004450
   PubMed Web of Science ®Google Scholar
• Vedovati MC, Germini F, Agnelli G, Becattini C. Direct oral anticoagulants in patients with VTE and cancer. Chest. 2015;147(2):475–483. doi:10.1378/chest.14-0402
   PubMed Web of Science ®Google Scholar
• Li A, Garcia DA, Lyman GH, Carrier M. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis. Thromb Res. 2019;173:158–163. doi:10.1016/j.thromres.2018.02.144
   PubMed Web of Science ®Google Scholar
• Kim JH, Yoo C, Seo S, et al. A Phase II study to compare the safety and efficacy of direct oral anticoagulants versus subcutaneous dalteparin for cancer-associated venous thromboembolism in patients with advanced upper gastrointestinal, hepatobiliary and pancreatic cancer: PRIORITY. Cancers. 2022;14(3). doi:10.3390/cancers14030559
   Web of Science ®Google Scholar
• White RH, Ginsberg JS. Low-molecular-weight heparins: are they all the same? Review Br J Haematol. 2003;121(1):12–20. doi:10.1046/j.1365-2141.2003.04196.x
   PubMed Web of Science ®Google Scholar
• Schrag D, Uno H, Rosovsky R, et al. Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial. JAMA. 2023;329(22):1924–1933. doi:10.1001/jama.2023.7843
   PubMed Web of Science ®Google Scholar
• Athanazio RA, Ceresetto JM, Marfil Rivera LJ, et al. Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism: a Latin American perspective. Clin Appl Thromb Hemost. 2022;28:10760296221082988. doi:10.1177/10760296221082988
   Web of Science ®Google Scholar
• Lee LH, Danchaivijitr P, Uaprasert N, et al. Safe and effective treatment of venous thromboembolism associated with cancer: focus on direct oral anticoagulants in Asian patients. Exp Hematol Oncol. 2022;11(1):79. doi:10.1186/s40164-022-00331-9
   PubMed Web of Science ®Google Scholar
• Kraaijpoel N, Di Nisio M, Mulder F, et al. Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE cancer study. Thromb Haemost. 2018;118(08):1439–1449. doi:10.1055/s-0038-1667001
   PubMedGoogle Scholar
• Ageno W, Vedovati MC, Cohen A, et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thromb Haemost. 2021;121(05):616–624. doi:10.1055/s-0040-1720975
   PubMed Web of Science ®Google Scholar
• Sabatino J, De Rosa S, Polimeni A, Sorrentino S, Indolfi C. Direct oral anticoagulants in patients with active cancer. JACC. 2020;2(3):428–440. doi:10.1016/j.jaccao.2020.06.001
   Google Scholar
• Cohen A, Keshishian A, Lee T, et al. Effectiveness and safety of apixaban, low-molecular-weight heparin, and warfarin among venous thromboembolism patients with active cancer: a U.S. claims data analysis. Thromb Haemost. 2021;121(03):383–395. doi:10.1055/s-0040-1718728
   PubMed Web of Science ®Google Scholar
• Cohen A, Keshishian A, Lee T, et al. Effectiveness and safety of apixaban, low-molecular weight heparin, and warfarin among high-risk subgroups of venous thromboembolism patients with active cancer. Eur Heart J. 2020;41(Supplement_2):ehaa946. doi:10.1093/ehjci/ehaa946.3369
   Google Scholar
• Giustozzi M, Agnelli G, Del Toro-Cervera J, et al. Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and meta-analysis. Thromb Haemost. 2020;120(07):1128–1136. doi:10.1055/s-0040-1712098
   PubMed Web of Science ®Google Scholar
• Haykal T, Zayed Y, Deliwala S, et al. Direct oral anticoagulant versus low-molecular-weight heparin for treatment of venous thromboembolism in cancer patients: an updated meta-analysis of randomized controlled trials. Thromb Res. 2020;194:57–65. doi:10.1016/j.thromres.2020.06.025
   PubMed Web of Science ®Google Scholar
• Mulder FI, Bosch FTM, Young AM, et al. Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. Blood. 2020;136(12):1433–1441. doi:10.1182/blood.2020005819
   PubMed Web of Science ®Google Scholar
• Saleem M, Osman M, Farid S, et al. Direct oral anticoagulants for treatment of venous thromboembolism associated with cancer: a systematic review and meta-analysis. Clin Oncol Res. 2020:3(6)1–7. doi:10.31487/j.COR.2020.06.14
   PubMedGoogle Scholar
• Tao DL, Olson SR, DeLoughery TG, Shatzel JJ. The efficacy and safety of DOACs versus LMWH for cancer‐associated thrombosis: a systematic review and meta‐analysis. Eur J Haematol. 2020;105(3):360–362. doi:10.1111/ejh.13453
   PubMed Web of Science ®Google Scholar
• Haykal T, Adam S, Ortel TL. Meta-analysis fever in the wake of CARAVAGGIO. Thromb Res. 2020;196:141–142. doi:10.1016/j.thromres.2020.08.036
   PubMed Web of Science ®Google Scholar
• Alsheef M, Bazarbashi S, Warsi A, et al. The Saudi consensus for the management of cancer-associated thromboembolism: a modified Delphi-based study. TH Open. 2023;7(1):e14–e29. doi:10.1055/s-0042-1758856
   PubMedGoogle Scholar
• National Institute for Health and Care Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing, NICE Guideline NG158. 2020. Available from: https://www.nice.org.uk/guidance/ng158. Accessed August 16, 2021.
   Google Scholar
• Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol. 2023;41(16):3063–3071. doi:10.1200/jco.23.00294
   PubMed Web of Science ®Google Scholar
• Farge D, Frere C, Connors JM, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022;23(7):e334–e347. doi:10.1016/s1470-2045(22)00160-7
   PubMed Web of Science ®Google Scholar
• Falanga A, Ay C, Di Nisio M, et al. Venous thromboembolism in cancer patients: ESMO clinical practice guideline. Ann Oncol. 2023;34(5):452–467. doi:10.1016/j.annonc.2022.12.014
   PubMed Web of Science ®Google Scholar
• Vedovati MC, Giustozzi M, Becattini C. Venous thromboembolism and cancer: current and future role of direct-acting oral anticoagulants. Thromb Res. 2019;177:33–41. doi:10.1016/j.thromres.2019.02.031
   PubMed Web of Science ®Google Scholar
• Kahn SR, Springmann V, Schulman S, et al. Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting: the Recovery study. Thromb Haemost. 2012;108(09):493–498. doi:10.1160/TH12-03-0169
   PubMedGoogle Scholar
• van der Wall SJ, Klok FA, den Exter PL, et al. Continuation of low-molecular-weight heparin treatment for cancer-related venous thromboembolism: a prospective cohort study in daily clinical practice. J Thromb Haemost. 2017;15(1):74–79. doi:10.1111/jth.13563
   PubMed Web of Science ®Google Scholar
• McBane R, Loprinzi C, Dakhil S, et al. Extending venous thromboembolism secondary prevention with apixaban in cancer patients: EVE trial. Eur J Haematol. 2020;104(2):88–96.
   PubMed Web of Science ®Google Scholar
• Connors JM. NATF cancer-associated thrombosis project: introduction. Oncologist. 2021;26(1):e1–e1. doi:10.1002/onco.13615
   PubMed Web of Science ®Google Scholar
• Wang T-F, Billett HH, Connors JM, Soff GA. Approach to cancer-associated thrombosis: challenging situations and knowledge gaps. Oncologist. 2021;26(1):e17–e23. doi:10.1002/onco.13570
   PubMed Web of Science ®Google Scholar
• Clemens A, Noack H, Brueckmann M, Lip GYH. Twice- or once-daily dosing of novel oral anticoagulants for stroke prevention: a fixed-effects meta-analysis with predefined heterogeneity quality criteria. PLoS One. 2014;9(6):e99276. doi:10.1371/journal.pone.0099276
   PubMed Web of Science ®Google Scholar
• Ageno W, Beyer-Westendorf J, Rubboli A. Once- versus twice-daily direct oral anticoagulants in non-valvular atrial fibrillation. Expert Opin Pharmacother. 2017;18(13):1325–1332. doi:10.1080/14656566.2017.1361405
   PubMed Web of Science ®Google Scholar
• Sepanlou SG, Malekzadeh F, Delavari F, et al. Burden of gastrointestinal and liver diseases in Middle East and North Africa: results of global burden of diseases study from 1990 to 2010. Middle East J Dig Dis. 2015;7(4):201–215.
   PubMedGoogle Scholar
• Adeloye D, Harhay MO, Ayepola OO, et al. Estimate of the incidence of bladder cancer in Africa: a systematic review and Bayesian meta-analysis. Int J Urol. 2019;26(1):102–112. doi:10.1111/iju.13824
   PubMed Web of Science ®Google Scholar
• Richters A, Aben KKH, Kiemeney LALM. The global burden of urinary bladder cancer: an update. World J Urol. 2020;38(8):1895–1904. doi:10.1007/s00345-019-02984-4
   PubMed Web of Science ®Google Scholar
• Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of bladder cancer. Med Sci. 2020;8(1):15. doi:10.3390/medsci8010015
   Google Scholar
• Carney BJ, Uhlmann EJ, Puligandla M, et al. Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors. J Thromb Haemost. 2019;17(1):72–76. doi:10.1111/jth.14336
   PubMed Web of Science ®Google Scholar
• Cohen A, Noxon V, Dhamane A, et al. Effectiveness and safety of anticoagulants among venous thromboembolism cancer patients with and without brain cancer. Thromb Res. 2023;226:117–126. doi:10.1016/j.thromres.2023.04.009
   PubMed Web of Science ®Google Scholar
• Gelosa P, Castiglioni L, Tenconi M, et al. Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs). Pharmacol Res. 2018;135:60–79. doi:10.1016/j.phrs.2018.07.016
   PubMed Web of Science ®Google Scholar
• Verso M, Munoz A, Bauersachs R, et al. Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. Eur J Cancer. 2021;148:371–381. doi:10.1016/j.ejca.2021.02.026
   PubMed Web of Science ®Google Scholar
• Al-Kindi SG, Oliveira GH. Prevalence of preexisting cardiovascular disease in patients with different types of cancer. Mayo Clin Proc. 2016;91(1):81–83. doi:10.1016/j.mayocp.2015.09.009
   PubMed Web of Science ®Google Scholar
• Mamas MA, Brown S-A, Sun LY. Coronary artery disease in patients with cancer: it’s always the small pieces that make the bigger picture. Mayo Clin Proc. 2020;95(9):1819–1821. doi:10.1016/j.mayocp.2020.07.006
   PubMed Web of Science ®Google Scholar
• Cohen A, Agnelli G, Buller H, et al. Characteristics and outcomes in patients with venous thromboembolism taking concomitant anti-platelet agents and anticoagulants in the AMPLIFY trial. Thromb Haemost. 2019;119(03):461–466. doi:10.1055/s-0038-1676983
   PubMedGoogle Scholar
• Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380(16):1509–1524. doi:10.1056/NEJMoa1817083
   PubMed Web of Science ®Google Scholar
• Potere N, Di Nisio M, Porreca E, et al. Apixaban thromboprophylaxis in ambulatory patients with cancer and obesity: insights from the AVERT trial. Thromb Res. 2023;226:82–85. doi:10.1016/j.thromres.2023.04.015
   PubMed Web of Science ®Google Scholar
• Giorgi-Pierfranceschi M, Lopez-Nunez JJ, Monreal M, et al. Morbid obesity and mortality in patients with VTE: findings from real-life clinical practice. Chest. 2020;157(6):1617–1625. doi:10.1016/j.chest.2019.12.040
   PubMed Web of Science ®Google Scholar
• Jegatheswaran J, Hundemer GL, Massicotte-Azarniouch D, Sood MM. Anticoagulation in patients with advanced chronic kidney disease: walking the fine line between benefit and harm. Can J Cardiol. 2019;35(9):1241–1255. doi:10.1016/j.cjca.2019.07.001
   PubMed Web of Science ®Google Scholar
• Harfouche M, Chemaitelly H, Kouyoumjian SP, et al. Hepatitis C virus viremic rate in the Middle East and North Africa: systematic synthesis, meta-analyses, and meta-regressions. PLoS One. 2017;12(10):e0187177. doi:10.1371/journal.pone.0187177
   PubMed Web of Science ®Google Scholar
• Poortahmasebi V, Baghi HB. Living in the shadows of hepatitis. Lancet Infect Dis. 2019;19(11):1171–1172. doi:10.1016/S1473-3099(19)30534-1
   PubMed Web of Science ®Google Scholar